Selecta Biosciences is a clinical-stage biopharmaceutical company using its ImmTOR immune tolerance platform to amplify the efficacy of biologics, including enabling the re-dosing of life-saving gene therapies, and restoring self-tolerance in autoimmune diseases. Co.'s ImmTOR platform encapsulates rapamycin, also known as sirolimus, an immunomodulator, in biodegradable nanoparticles and is designed to induce antigen-specific immune tolerance. Co.'s product candidate, SEL-212, is designed to be a monthly treatment for chronic refractory gout. Co. is also combining ImmTOR with an immunoglobulin A (IgA) protease for the treatment of IgA nephropathy, an autoimmune kidney disease. The SELB stock yearly return is shown above.
The yearly return on the SELB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SELB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|